US · Healthcare · Biotechnology
EPS came in at -0.38 against a street estimate of -0.36 — a miss of 5.6%.
Analysts rate Oric Pharmaceuticals Inc a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $20.67.
| Fund | Stake |
|---|---|
| Nextech Invest, Ltd. | 6.91% |
| EcoR1 Capital, LLC | 6.49% |
| BlackRock Inc | 5.77% |
| Viking Global Investors LP | 5.62% |
| T. Rowe Price Associates, Inc. | 5.20% |
| Pfizer Inc | 4.61% |
| SR ONE CAPITAL MANAGEMENT, LP | 4.45% |
| VR Adviser, LLC | 4.17% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ORIC PHARMACEUTICALS, INC. – 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash and investments: $37.5 million cash + $227.3 million short-te | 2026-08-03 |
| Results announced · Q3 2026 ORIC PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and investments: $387.6 million as of June 30, 2026 • Runwa | 2026-08-03 |
| Board / officer change · Q3 2026 ORIC PHARMACEUTICALS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) • Filing Date: July 30, 2026 (reporti | 2026-07-30 |
| Board / officer change · Q2 2026 ORIC PHARMACEUTICALS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 18, 2026 • 94,571,281 shares represented at meeting | 2026-06-22 |
| Quarterly report · Q1 2026 ORIC PHARMACEUTICALS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Investments: $419.7 million in total liquid assets (cash $56.4M + short- | 2026-05-04 |
| Results announced · Q2 2026 ORIC PHARMACEUTICALS Q1 2026 SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and investments: $419.7 million as of March 31, 2026 (includes $59.9 | 2026-05-04 |
| Proxy statement · Q2 2026 ORIC PHARMACEUTICALS, INC. – 2026 PROXY SUMMARY CEO COMPENSATION • Jacob M. Chacko, M.D., President and Chief Executive Officer – Total compensation | 2026-04-28 |
| Annual report FY2025 ORIC PHARMACEUTICALS, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): $862.4 million • Outs | 2026-02-23 |
Readable in the app.
| Announcement | Date |
|---|---|
| Clinical trial collaboration and supply agreement with Bayer ORIC Pharmaceuticals, a clinical-stage oncology company, announced progress on two main drug candidates. The company initiated Himalayas-1, a global Phase 3 trial testing rinzimetostat (a ca | 2026-08-03 |
| Phase 3 trial initiation planned; multiple clinical updates expected in 2H 2026 ORIC Pharmaceuticals reported progress on its two lead cancer programs. For rinzimetostat (a PRC2 inhibitor for prostate cancer), the company selected the 400mg daily dose for its Phase 3 Hi | 2026-05-04 |
| Raised capital; extended cash runway into 2H 2028 and beyond ORIC Pharmaceuticals reported strong 2025 results with significant clinical and financial progress. The company's two lead programs showed promising data: rinzimetostat demonstrated 'best-in | 2026-02-23 |
| Q3 2025 results; clinical updates on ORIC-944 and enozertinib programs ORIC Pharmaceuticals reported encouraging clinical progress for its two lead cancer drugs. For ORIC-944 (prostate cancer treatment), the company completed dose-finding studies and selected r | 2025-11-13 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Oric Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.